Market Views – Page 19 – media

Insightec closes $150m Series E

HAIFA, Israel and MIAMI, Florida – INSIGHTEC®, a commercial-stage medical technology company revolutionizing surgery with incisionless MRI-guided focused ultrasound (MRgFUS) announced today the closing of a $150 million Series E private equity investment round. Koch Disruptive Technologies (KDT), a subsidiary of Koch Industries, focused on finding and funding innovative and emerging companies, led the round with a $100 million investment.
- Source: drugdu
- 514
- February 6, 2018
Market Views MRgFUS non-invasive treatments
Why healthcare cybersecurity spending will exceed $65B over the next 5 years

Hospitals and healthcare providers remain under cyber attack, causing organizations to spend more to protect their systems and patient data.
- Source: CSO Online
- 556
- February 6, 2018
cybersecurity digital health Market Views
Hospitals turn to mobile devices to cut costs, study shows

More than nine in 10 nurse managers see voice recognition and telehealth technologies intensifying over the next five years, while secure text messaging, voice communication and photographing wounds and skin conditions will be nearly universal. Major growth is expected in areas like remote patient monitoring.
- Source: Healthcare Dive
- 736
- February 5, 2018
digital health Market Views medical device
Wearable devices for business vs. fitness

Wearables, like smartwatches and fitness trackers, are popular with business professionals, and for good reason. The devices can collect data and provide insights, allowing wearers to track their fitness and productivity to reach their goals faster.
- Source: Tech Republic
- 687
- February 5, 2018
Internet of Things Market Views medical device wearables
The Future of Pharmacy

The interest in Blockchain and distributed ledger technology (DLT) has exploded in recent years with a large focus on the financial industry. Meanwhile, medical and pharmaceutical companies around the world are looking to DLT as a means of solving, securing, and streamlining their businesses. While there are many applications for DLT within the medical industry, one area where the technology excels is within supply chains.
- Source: Blockchain Healthcare Review
- 696
- February 5, 2018
blockchain Market Views pharmaceutical drugs
Japanese pharma set for transformation in 2018

This year could see a transformation in the Japanese pharma market, according to a new report, with strong growth stemming from increased use of generics, biosimilars and stronger links with the global industry.
- Source: PharmaPhorum
- 946
- February 2, 2018
biosimilars CPhI Market Views pharmaceutical
Digital health had record funding year, but noticeable drop in exits

In many ways, 2017 was a banner year for digital health funding, according to Rock Health's annual report, which puts funding for the year at a record $5.8 billion.
- Source: Mobi Health News
- 475
- February 2, 2018
digital health investment Market Views
Seattle Genetics Snaps Up Cascadian in $614M Buyout Deal

The year’s merger-and-acquisition trend continues. Today, the last day of January, Bothell, Washington-based Seattle Genetics announced it is buying Seattle-based Cascadian Therapeutics for about $614 million.
- Source: Biospace
- 458
- February 1, 2018
Cascadian HER2 Market Views merger-and-acquisition
BridgeBio Pharma Licenses Late-Stage Oncology Drug Infigratinib to Tackle FGFR-Driven Maladies; Establishes New Subsidiary QED Therapeutics with $65 Million in Initial Financing

BridgeBio Pharma today announced that it is has licensed infigratinib (BGJ398), a highly potent and selective inhibitor of the tyrosine kinase receptor FGFR, from Novartis. In addition, BridgeBio announced that it was launching new subsidiary QED Therapeutics to drive development of infigratinib with an initial financial commitment of $65 million.
- Source: Prnewswire
- 606
- February 1, 2018
achondroplasia infigratinib (BGJ398) Market Views Novartis QED Therapeutics
Adverum Biotechnologies and Editas Medicine Extend Research Collaboration

Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced today an extension of its collaboration agreement with Editas Medicine, Inc. (Nasdaq:EDIT). The companies established this collaboration to explore the delivery of genome editing medicines to treat up to five inherited retinal diseases.
- Source: investors.adverum
- 466
- January 31, 2018
genome editing Market Views retinal diseases

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.